Patent ID: 11957749
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 4:
5. A kit comprising the following components:
a) a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a polynucleotide encoding a hepatitis B virus core antigen (HBc);
b) a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a polynucleotide a hepatitis B virus core antigen (HBc), wherein the polynucleotides encoding HBs and HBc are separated by a polynucleotide encoding the 2A cleaving region of the foot and mouth disease virus (FMDV); and
c) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B virus core antigen (HBc) comprising amino acids 1-145, 1-146, 1-147, 1-148, or 1-149 of a wild-type hepatitis B core antigen protein, and an adjuvant,
with instructions for administration of the components sequentially or concomitantly for the treatment of chronic hepatitis B (CHB).